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Background: Extracts of the plant Hypericum perforatum L. have been traditionally used in folk medicine
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shown to be effective in animal models of depression.
Objective: We investigated if 2 xanthone derivatives (1101 and 1105) were as effective as venlafaxine,
which is a serotonin–norepinephrine reuptake inhibitor and was used as a positive control, in animal
models of depression.
Methods: A series of derivatives from xanthone were designed and synthesized. After preliminary
experiments, 2 xanthone derivatives (1101 and 1105) were considered to be effective in our mouse
depression model. To further determine their effects on depression, classical behavioral despair animal
models (forced swim and tail suspension tests) were used to assess the efﬁcacies of these derivatives,
whereas venlafaxine hydrochloride was used as a positive control. Oral acute toxicity studies were used
to determine if the derivatives were toxic in mice.
Results: The oral acute toxicity studies of 2 xanthone derivatives (1101 and 1105) did not show any toxic
effect until the dose at 1000 mg/kg body weight, and xanthone derivatives 1101 and 1105 resulted in a
signiﬁcant decrease of the immobility period (in seconds) compared with the untreated control group
during the forced swim test with rats (dose ¼ 12 mg/kg; P o 0.05) and mice (dose ¼ 25 mg/kg; P o
0.001). At lower doses, derivatives 1101 and 1105 also decreased the immobility period of rats and mice
during the forced swim test but signiﬁcant differences were only found in mice compared with the
untreated control group (P o 0.05). No difference was found between the groups treated with xanthone
derivatives and the positive control group during the swimming period in both mice (dose ¼ 25 mg/kg)
and rats (dose ¼ 12 mg/kg) (P 4 0.05). In the tail suspension test, derivatives 1101 and 1105 produced
marked effects with regard to the motion of mice (P o 0.01 or 0.001, respectively) and the derivatives
were also noted to have some effects on rats at a dose of 12 mg/kg (P o 0.05). Compared with the
positive venlafaxine control group, no differences were found between those treated with either
derivative 1101 or derivative 1105 and venlafaxine (P 4 0.05).
Conclusions: Within certain dose ranges, xanthone derivatives 1101 and 1105 have similar effects to
venlafaxine hydrochloride in the treatment of depression as suggested by behavioral despair animal
models using rats and mice.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Depression is a common mental disorder characterized by
pronounced and long-lasting depressed mood, as well as a variety
of additional symptoms (behavioral, affective, and cognitive). TheInc. This is an open access article
College of Pharmacy, Nanjing
ou District, Nanjing 210009,number of patients with depression has increased dramatically in
recent decades and, according to the World Health Organization, it
is projected to become the second largest contributor to the global
burden of disease by the year 2020.1
Drug treatment is 1 of the most effective tools used to deal with
depression. At present, a variety of antidepressant medications are
available that have shown beneﬁcial effects. However, all are
known to exert adverse side effects, and some are very expensive.
Additional treatment modalities with little risk, credible beneﬁt,
and moderate costs would be useful additions to depression
management.under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Fig. 1. Chemical structures of (A) xanthone, and the derivatives of (B) xanthone
1101 and (C) xanthone 1105 used in this study
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which such compounds could be selected for investigation.2 In
recent years, Hypericum perforatum L. (HPL) has become a focus of
research interest and investigated for its therapeutic effects with
regard to mood disorders, and its antidepressive action has been
demonstrated in animals and humans.3 Consequently, in Germany,
extracts of HPL have been licensed for the treatment of depression.
Indeed, HPL extracts have been found to be more effective than
placebos in the treatment of mild to moderate depression,4 and as
effective as several tricyclic antidepressants and ﬂuoxetine.5 The
antidepressant activity of HPL is thought to stem from the
presence of ﬂavonoids. Xanthone (Figure 1A) is 1 such ﬂavonoid,
and can be isolated from the aerial parts of HPL.6 Furthermore,
xanthone has been shown to be a prototype drug useful in the
treatment of depression,7 and its derivatives have been shown to
have potential antidepressant activity via forced swim tests
(FSTs).8
To modify the structure of xanthone and promote its activity to
compete with selective serotonin reuptake inhibitors in terms of
efﬁcacy, a series of xanthone derivatives were designed and
synthesized in this study. After preliminary experiments, 2 deriv-
atives (1101 and 1105) (Figure 1B–1C) were considered to be
effective following mice swimming test models. Subsequently,
FSTs and tail suspension tests (TSTs) were used to detect their
effects with regard to depression in rats and mice. Our results
suggest that the 2 derivatives effectively improve behavioral
despair symptoms in rats and mice compared with negative
controls and may be as effective as venlafaxine at certain doses.Materials and Methods
Animals
Male imprinting control region mice weighing between 18 and
22 g were commercially obtained from the Sino-British SIPPR/BK
Lab (Shanghai, China). Male Wistar rats weighing between 150 and
170 g were obtained from the experimental animal center of the
Military Medical Science Academy of the Chinese People’s Liber-
ation Army (Beijing, China). The animals were maintained under a
standard 12-hour light/dark cycle (lights on at 8:00 AM) at a
constant temperature of 221C (711C) and mean (SD) relative
humidity of 45% (15%) with free access to food and water, except
for periods of water and food deprivation. Animals were acclim-
atized to laboratory conditions before the experiment. Each animal
was used only once. The experiments were performed between9:00 AM and 3:00 PM. The procedures in this study were performed
in accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. Maximal effort was made to
minimize animal trauma and the number of animals necessary for
the acquisition of reliable data. All experiments were approved by
our local ethics committee.
Oral acute toxicity studies in mice
The derivative (1101 or 1105) was weighed and resuspended
with 0.5% hydroxymethyl cellulose aqueous solution to obtain the
desired concentrations. Mice were starved overnight (16 hours)
before feeding with a single oral dose of derivative. Animals were
divided into 7 groups of 10 (5 males and 5 females for each group).
Mice in each group were fed derivatives (1101 or 1105) at a single
oral dose of 250, 500, or 1000 mg/kg body weight for each
derivative, respectively; the control group received a single oral
dose of 0.5% hydroxymethyl cellulose aqueous solution. General
behavior of each mouse was observed continuously for 1 hour
after each dose, intermittently every 4 hours for three times, and
thereafter over a period of 24 hours.9 Animals were observed for
up to 14 days for any sign of toxicity (eg, behavior change related
to central nervous, cardiovascular, and gastrointestinal systems),
body weight change, and water and food consumption. At the end
of the observation period, all animals were sacriﬁced under ether
anesthesia and vital organs (heart, lung, liver, spleen, and kidney)
were removed from all animals for gross and histopathologic
examination.
FST
Mice were individually forced to swim inside a polycarbonate
cylinder (height ¼ 24 cm; diameter ¼ 16 cm) containing 20 cm
water at 251C. Mice were allowed to swim for a total of 6 minutes;
a camcorder (Sony Handycam; Sony Corporation of America, New
York, New York) recorded the swim session. Digital video output
was analyzed by a computer running SMART Video Tracking
System software (Panlab, Barcelona, Spain). The swimming time
during the experiment was measured with SMART software. It
should be noted that the water was changed before the next
animal was placed into the cylinder. Clean water was used for each
behavior trial because used water has been shown to alter
behavior due to an alarm signal.10 Mice were returned to cages
after testing and dried.
The modiﬁed rat FST described by Lucki11 suggests that rats
should swim for 15 minutes in a polycarbonate cylinder (height ¼
46 cm; diameter ¼ 21 cm) containing 30 cm water at 251C, with a
5-minute test period recorded. In our study we modiﬁed this
protocol and allowed rats to swim for 12 minutes. The swimming
sessions were recorded by camera but only the ﬁnal 8 minutes
were analyzed by a SMART Video Tracking system. In accordance
with the mouse FST protocol, the water was changed after each
animal was tested, and rats were returned to the cages after
swimming and dried.
TST
The TST was carried out according to the method of Steru
et al.12 Mice were suspended on a small metal hook ﬁxed on the
top of a box via adhesive tape placed approximately 1 cm from the
tip of the tail. The duration of the immobility period was recorded
with a SMART system. The recordings were performed for a total of
6 minutes and data were analyzed with SMART software.
The TSTs with rats were performed as described above for
mice; however, the recording time was 9 minutes. The ﬁnal
6 minutes of the process were analyzed with SMART software.
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Fig. 2. Antidepressant-like effect of xanthone derivatives in mice following forced swim test. Data are represented as the mean seconds (SEM) of the total swim period
during a 6-minute session. Xanthone derivatives 1101 and 1105 were administered 1 hour before testing and venlafaxine hydrochloride was administered 45 minutes before
testing. Each group contained 8 to 9 mice. *P o 0.05; †P o 0.01; ‡P o 0.001 versus vehicle-treated mice; §P o 0.05; ǁP o 0.01 versus venlafaxine hydrochloride-
treated mice.
Table I
ANOVA results for mice forced swim test (MFST) and mice tail suspension test
(MTST) following administration of substances.
Mouse groups
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Xanthone derivatives 1101 and 1105 were provided by the Plant
Chemical Laboratory of Jiangsu Institute of Materia Medica Co, Ltd
(Nanjing, China). Venlafaxine hydrochloride was obtained from
Chengdu Kanghong Pharmaceutical Group Co, Ltd (Chengdu,
China). All the derivatives were suspended in 0.5% hydroxymethyl
cellulose aqueous solution and diluted to the desired concentra-
tion. Hydroxymethyl cellulose aqueous solution (0.5%) was used as
a negative control.
Mice were given oral doses of 6.25, 12.5, or 25 mg/kg/d
derivative 1101 or 1105, 16 mg/kg/d venlafaxine hydrochloride,
or the negative control vehicle for 3 days. At Day 3, mice were
given derivatives 1101 or 1105 or the negative control vehicle
1 hour before the swimming test. Positive control animals received
venlafaxine hydrochloride 45 minutes before the test. SMART
software was used for data processing.
Rats were given oral doses of 3, 6, or 12 mg/kg/d derivative
1101 or 1105, 8 mg/kg/d venlafaxine hydrochloride, or the negative
control vehicle for 3 days. Other procedures were carried out in
accordance with the mouse FST protocol.
All procedures were performed single-blind; that is,
1 researcher administered the drugs and another researcher
performed data collection.
Statistical analysis
Results are expressed as mean seconds (SEM). All data were
analyzed using SPSS 13.0 software (IBM-SPSS Inc, Armonk, New
York). The signiﬁcance of the difference in the responses of the
treatment groups in comparison to the control was determined by
1-way ANOVA. Fisher least squares difference test was used to
further analyze signiﬁcant differences. All analyses were 2-tailed
and used an α r 0.05 to determine signiﬁcance.Vehicle,* venlafaxine (16 mg/kg),
and derivative 1101 (6.25, 12.5, and
25 mg/kg)
Vehicle,* venlafaxine (16 mg/kg),
and derivative 1105 (6.25, 12.5, and
25 mg/kg)
Test F P F P
MFST 8.235 0.000 5.496 0.001
MTST 14.495 0.000 18.009 0.000
n Vehicle (negative control) group received a single oral dose of 0.5% hydro-
xymethyl cellulose aqueous solution.Results
Acute oral toxicity study
The toxicity of derivatives (1101 and 1105) when given as a
single oral dose in mice was investigated to deﬁne the optimal
dose of derivatives to be used for evaluation of its in vivo
antidepressant activity in behavioral despair animal models.Results indicated virtually no toxicity at a single oral dose of
1000 mg/kg body weight for each derivative (1101 or 1105). All
mice survived. There was neither sign of toxicity nor signiﬁcant
change in water and food consumption and body weights of mice
in all groups during the 14-day observation period. The gross
examination of vital organs (ie, heart, lung, liver, spleen, and
kidney) in all treated (all dose levels) and control groups were
similar either in size or cell morphology. Therefore, it was
concluded that the dose up to1000 mg/kg for each derivative
(1101 or 1105) was safe.Effect of xanthone derivatives on FSTs
Our experiment was carried out according to a previously
described method.13 After the initial 2 to 3 minutes of vigorous
activity, the animals displayed a period of immobility and ﬂoated
with minimal movements. Some animals remained ﬂoating pas-
sively in the water in a slightly hunched but upright position with
the nose above the surface of the water. All of the administered
substances investigated in our study, including venlafaxine hydro-
chloride, increased the swimming period in mice (in seconds)
compared with the negative control group in mouse FSTs. Figure 2
and Table I show that venlafaxine hydrochloride (16 mg/kg)
signiﬁcantly increased the swimming period of mice (P o
0.001). The tested substances 1101 and 1105 signiﬁcantly pro-
longed the swimming period of mice also within a dose range of
6.25 to 25 mg/kg (P o 0.05 or 0.001). No difference was found
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Fig. 3. Effects of xanthone derivatives in the rat forced swim test. Data are represented as the mean seconds (SEM) of the total swim period during the ﬁnal 8 minutes of a
12-minute session. Xanthone derivatives 1101 and 1105 were administered 1 hour before testing and venlafaxine hydrochloride was administered 45 minutes before testing.
Each group contained 8 or 9 rats. *P o 0.05; †P o 0.01; ‡P o 0.001 versus vehicle-treated rats; §P o 0.05; zP o 0.001 versus venlafaxine hydrochloride-treated rats.
X. Zhao et al. / Current Therapeutic Research 76 (2014) 45–5048between the mice treated with substances 1105 or 1101 (25 mg/kg)
and the positive control group (P 4 0.05).
To observe the effect of these substances in different animal
models, male Wistar rats were also assessed. During the experi-
ment, the recording time was modiﬁed to 8 minutes. Our results
show that derivative 1101 and derivative 1105 at a dose of 12 mg/
kg resulted in a decrease of the immobility period with respect to
the negative control (P o 0.05) (Figure 3 and Table II). In addition,
derivative 1105 at a dose of 6 mg/kg resulted in a decrease of the
immobility period with respect to the negative control (P o 0.01)
(Figure 3 and Table II). Lower doses were noted to decrease the
immobility period, but no signiﬁcant difference was found com-
pared with the negative control group. Venlafaxine hydrochloride
(8 mg/kg) increased the swimming period signiﬁcantly in rats
(P o 0.001), which was in accordance with the FSTs performed
with mice. No signiﬁcant difference was found between rats that
received derivative 1105 or 1101 (12 mg/kg) and the positive
control (P 4 0.05).
Effect of xanthone derivatives on TSTs
In the experiments, oral doses of 6.25, 12.5, or 25 mg/kg
derivatives 1101 or 1105 signiﬁcantly increased the activity period
of mice (P o 0.01 or 0.001, respectively) compared with the
negative control group. Venlafaxine hydrochloride (16 mg/kg) also
resulted in a decrease of the immobility period with respect to the
negative control group (P o 0.001) (Figure 4 and Table I). No
signiﬁcant difference was found between substances 1105 or 1101
(25 mg/kg) and the positive control group with regard to the
activity period during the mouse TST (P 4 0.05).Table II
ANOVA results for rat forced swim test (RFST) and rat tail suspension test (RTST)
following administration of substances.
Rat groups
Vehicle,* venlafaxine (8 mg/kg),
and derivative 1101 (3, 6, and 12
mg/kg)
Vehicle,* venlafaxine (8 mg/kg),
and derivative 1105 (3, 6, and 12
mg/kg)
Test F P F P
RFST 8.671 0.000 3.197 0.024
RTST 1.628 0.190 2.519 0.060
n Vehicle (negative control) group received a single oral dose of 0.5% hydro-
xymethyl cellulose aqueous solution.In the TSTs of rats all therapeutic agents decreased the
immobility period, but only a dose of 12 mg/kg 1101 or 1105
resulted in a signiﬁcant difference (P o 0.05) compared with the
negative control group. Although venlafaxine hydrochloride
(8 mg/kg) decreased the immobility period of rats, no difference
was found between the venlafaxine group and the control group
(Figure 5 and Table II). No signiﬁcant difference was found
between substances 1105 and 1101 and the positive control group
with regard to the activity period of rats during the suspension
tests (P 4 0.05).Discussion
Clinical depression is a common, chronic, recurrent, and debil-
itating condition associated with severe morbidity and signiﬁcant
mortality.14 Traditional and current pharmacotherapies for depres-
sion have targeted monoaminergic systems, especially the nora-
drenergic and serotonergic systems. Although many antidepres-
sants have been used in clinical settings, a number of them
lack efﬁcacy in more severe forms of depression.15 Conse-
quently, the discovery of effective antidepressants is of great
importance.
HPL, commonly known as St John’s wort, is a member of the
Hypericaceae family and is a herbaceous perennial plant that is
native to Europe, Northern Africa, Northern America, and China.16
HPL extracts contain at least 10 constituents or groups of compo-
nents that may contribute to its pharmacologic effects. These
include naphthodianthrons (ie, hypericins, the content of which
is standardized in most available preparations), ﬂavonoids (ie,
quercetin), xanthons, and biﬂavonoids.4 HPL extracts may modu-
late the activity of several neurotransmitters in the brain in a
speciﬁc manner depending on the concentrations of the active
derivatives contained within the extract, especially the ﬂavonoids,
which have been shown to effectively inhibit monoamine oxidase
activity.17 Previous research has suggested that acute administra-
tion of large doses of HPL extracts can change the content of
neurotransmitters; that is, 5-hydroxytryptamine, noradrenaline,
and dopamine, which are involved in the pathophysiology of mood
disorders.18 The more the extract was administered, the more
obvious and effective the inﬂuence was throughout the brain,
which involved the diencephalon and brainstem, which has
recently been implicated in the pathophysiology of depression.18
A component of HPL, xanthone has been shown to be effective
in mood disorders, such as depression.7 According to literature
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Fig. 4. Antidepressant-like effects of xanthone derivatives on tail suspension tests with mice. Data are represented as the mean seconds (SEM) of the total activity period
during a 6-minute session. Xanthone derivatives 1101 and 1105 were administered 1 hour before testing and venlafaxine hydrochloride was administered 45 minutes before
testing. Each group contained 8 or 9 mice. †P o 0.01; ‡P o 0.001 versus vehicle-treated mice; ǁP o 0.01; zP o 0.001 versus venlafaxine hydrochloride-treated mice.
X. Zhao et al. / Current Therapeutic Research 76 (2014) 45–50 49procedures, we consequently separated, puriﬁed, and modiﬁed the
HPL to obtain 10 derivatives of xanthone. To verify their effects on
depression, FSTs and TSTs with mice were used in a preliminary
experiment, and venlafaxine was used as a positive control.
According to Kulkarni et al,19 the dose range of venlafaxine for
mice in mouse TSTs should be 2 mg/kg/d to 16 mg/kg/d. Con-
sequently, we selected 16 mg/kg/d as the appropriate venlafaxine
positive control dose for the mice in our study. With regard to rats,
a dose of 8 mg/kg/d venlafaxine for 3 successive days was selected
as the appropriate dose. We calculated this according to the dose
conversion between different kinds of animals, and we then
conducted preliminary experiments with rats to ensure that
8 mg/kg/d was the most appropriate positive control dose.
According to the Kulkarni et al,19 drugs should be administered
30 minutes before testing. But in our preliminary tests, adminis-
tering the positive control 30 minutes before testing and the
derivatives 45 minutes before testing had no effect. Following
our preliminary tests, we found it reasonable to administer
venlafaxine 45 minutes before testing and our test compounds
1 hour before testing. The results of preliminary tests revealed that
2 derivatives (1101 and 1105) were effective in the behavioral
despair animal models. We subsequently repeated these experi-
ments in both mice and rats, and showed that derivatives 1101 and350
300
*
250
200
150
100
50
0
1101Vehicle Venlafaxine
hydrochloride
M
EA
N
 A
C
TI
VI
T
Y 
TI
M
E 
(s
, +
/-
 S
EM
)
Fig 5. Effects of xanthone derivatives in rat tail suspension tests. Data are represented as
9-minute session. Xanthone derivatives 1101 and 1105 were administered 1 hour before
Each group contained 8 or 9 rats. *P o 0.05; †P o 0.01 versus vehicle-treated rats.1105 were as effective in these models as venlafaxine (a serotonin–
norepinephrine reuptake inhibitor), which was used as a positive
control. This was particularly evident when high doses of our
derivatives were used.
In our studies, we found that mice and rats responded differently to
the therapeutic agents administered during the experiments, with rats
appearing to be especially sensitive. In preliminary rat FSTs we were
unable to repeat the results using the positive venlafaxine control and
the Lucki method11 because the rats struggled vigorously in the water
at ﬁrst, and then ﬂoated with minimum movements, even when
venlafaxine was administered during the recording time. Conse-
quently, we reduced the swimming time to 12 minutes and increased
the recording time to 8 minutes, which permitted an observable
difference between the negative control group and the positive
venlafaxine control group (P o 0.05, data not shown). In the rat TSTs
individual differences in the negative control groupwere larger than in
the other groups and we believe this resulted in no signiﬁcant
difference being observable between the negative control group and
the treated groups (Table II). We believe that animal strain may have
caused this variance, as reported in a review by Cryan et al.20
According to a Cochrane review focused on HPL,4 the tolerability
of HPL preparations was found to be good following assessment of a
number of randomized controlled clinical trials, and fewer adverse†
1105
12mg/kg
3mg/kg
6mg/kg
Vehicle
Venlafaxine hydrochloride
the mean seconds (SEM) of the total activity period during the ﬁnal 6 minutes of a
testing and venlafaxine hydrochloride was administered 45 minutes before testing.
X. Zhao et al. / Current Therapeutic Research 76 (2014) 45–5050effects were noted than with use of selective serotonin reuptake
inhibitors. In our study, acute toxicity studies of derivatives 1101
and 1105 revealed the nontoxic nature of the derivatives at doses up
to 1000 mg/kg, and no other toxic reactions were found with the
selected doses through the conclusion of the study.Conclusions
The results of our study suggest that xanthone derivatives 1101
and 1105 have antidepressant-like effects as demonstrated by behav-
ioral despair tests (FST and TST), and exert very little overt toxicity. The
antidepressant effects of these 2 xanthone derivatives are consistent
with the research of Jastrzebska Wiesek et al8 regarding xanthone
derivatives and their inﬂuence on the outcome of FSTs. According to
our study, these 2 derivatives may be useful in the treatment of
depression; however, further research is needed to investigate their
effects on chronic, unpredictable, mild stress models and neuro-
transmitter release in the brain to determine their mechanism of
action in behavioral despair models. We believe that the selection of
leading derivatives from natural products will become an accepted,
effective tool for the treatment of a variety of health conditions,
including depression, in the near future and our study adds weight to
the effective application of such derivatives in the medical ﬁeld.Acknowledgements
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